Skip to content
header-news_01

Aspen Healthcare News

Aspen announces exclusive licensing agreement with Wooshin Labottach for Lidocaine 700mg medicated plasters

June 26, 2024

Dublin, Ireland – Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of Aspen Pharmacare Holdings Limited, a JSE-listed global multinational specialty pharmaceutical company, is pleased to announce that it has successfully concluded an exclusive licensing agreement with the Republic of Korea-based Wooshin Labottach Co. LTD, for Lidocaine 700mg medicated plasters, in selected European Union (EU) markets.

Read More >>

Aspen concludes exclusive European licensing agreement with Devintec Pharma for a patented women’s health medical device 

June 12, 2024

Dublin, Ireland – Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of Aspen Pharmacare Holdings Limited, a JSE-listed global multinational specialty pharmaceutical company, has concluded an exclusive licensing agreement (“Agreement”) with Swiss-based Devintec Pharma (“Devintec”) for Europe.

Read More >>

Aspen EME Kick-Off Meeting 2024

February 22, 2024

In January, the Aspen EME team gathered to start the new year 2024 and the post-merger journey with purpose, passion and unity. During this event held in Istanbul, we had the opportunity to get to know each other better, share experiences from our different markets, learn, and celebrate accomplishments. We also had the pleasure of…

Read More >>

PharmaBoardroom interview with Daniel Vella Friggieri on the merger of Aspen Europe & MENAT regions

June 26, 2023

In this interview with PharmaBoardroom, Daniel Vella Friggieri, Regional CEO EME, outlines the rationale behind the merger of Europe & MENAT regions

Read More >>

New Aspen International Commercial Region – Europe & Middle East

March 17, 2023

Over the last few months, the Aspen Group Executives completed an in-depth review of the international commercial portfolio to ensure focus and alignment with Aspen’s business strategy geared towards delivering its stated objectives. This led to a strategic decision to merge the current Europe and MENAT regions into one growth region to achieve the objectives…

Read More >>

Aspen, Saudi Chemical Company Holding and its subsidiary AJA Pharma enter into a memorandum of understanding

March 7, 2023

Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational pharmaceutical company, has entered into a memorandum of understanding (“MOU”) with Saudi Chemical Company Holding (“SCCH”), a well-known company in the local market of the Kingdom of Saudi Arabia, and…

Read More >>

Aspen donates life-saving emergency relief to patients in Turkey and Syria

February 17, 2023

Aspen, a leading global specialty and branded multinational pharmaceutical company, has positively responded to humanitarian calls for relief following the devastating 7.8 magnitude earthquake, along with a series of strong tremors and aftershocks, that tore through southeast Turkey and northwest Syria on 6 February 2023.

Read More >>

Smile and skip the ouch!

December 8, 2022

We are very pleased to announce the launch of a website and social media pages that provide general information about Emla cream to the UAE audience.

Read More >>

AHC Kick-Off Meeting 2022

November 25, 2022

The Aspen MENAT team gathered in October 2022 for a Kick-Off Meeting that took place at the beautiful Museum of The Future in Dubai, and Jumeirah Emirates Towers Hotel. This two-day event in the UAE was a special opportunity to share experiences from our different markets, learn from one another, celebrate accomplishments, and have fun!…

Read More >>

Aspen and BIT Pharma enter into an exclusive agreement for a Nicardipine-based Intracerebral Implant 

October 28, 2022

Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational pharmaceutical company, has entered into an exclusive licensing agreement with Austrian-based biotech company Brain Implant Therapeutics (BIT) Pharma (“BIT Pharma”), for a Nicardipine-based intracerebral implant aimed at preventing vasospasm, a…

Read More >>
Scroll To Top